Last reviewed · How we verify
Estrogen vaginal cream
Estrogen vaginal cream delivers estrogen directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause.
Estrogen vaginal cream delivers estrogen directly to vaginal tissues to restore estrogen levels and relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause. Used for Vaginal atrophy and genitourinary syndrome of menopause, Vaginal dryness and dyspareunia in postmenopausal women.
At a glance
| Generic name | Estrogen vaginal cream |
|---|---|
| Also known as | Estrace Cream, Premarin Cream |
| Sponsor | The University of Texas Health Science Center, Houston |
| Drug class | Estrogen replacement therapy (topical) |
| Target | Estrogen receptor alpha and beta |
| Modality | Small molecule |
| Therapeutic area | Women's Health / Gynecology |
| Phase | FDA-approved |
Mechanism of action
The cream formulation allows topical application of estrogen to the vaginal epithelium, where it is absorbed locally to restore tissue elasticity, moisture, and blood flow. This addresses vaginal dryness, irritation, and dyspareunia associated with menopause or estrogen deficiency. The localized delivery minimizes systemic absorption compared to oral or transdermal estrogen.
Approved indications
- Vaginal atrophy and genitourinary syndrome of menopause
- Vaginal dryness and dyspareunia in postmenopausal women
Common side effects
- Vaginal irritation or burning
- Headache
- Breast tenderness
- Vaginal bleeding or spotting
Key clinical trials
- Silicone Gel vs. Estrogen Vaginal Cream for the Management of Genitourinary Syndrome of Menopause (NA)
- Topical Vaginal Estrogen for Postpartum Obstetric Anal Sphincter Injury Recovery (PHASE4)
- Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections (PHASE4)
- Er:YAG Laser Combined With Vaginal Estriol for Genitourinary Syndrome of Menopause (NA)
- Use of Topical Testosterone and Estrogen vs Estrogen Alone in Vulvodynia: a Randomized Controlled Trial (PHASE2, PHASE3)
- Hormonal Status on Blood Flow and Tissue in Pelvic Organ Prolapse (PHASE4)
- Periurethral vs Intravaginal Estrogen for Prevention of Recurrent Urinary Tract Infections (PHASE2)
- Vaginal Estrogen for Improvement of Outcomes Following Pelvic Organ Prolapse Surgery (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Estrogen vaginal cream CI brief — competitive landscape report
- Estrogen vaginal cream updates RSS · CI watch RSS
- The University of Texas Health Science Center, Houston portfolio CI